Type 1 interferons as a potential treatment against COVID-19

Antiviral Research

Volumn 178, Issue , 2020, Pages

  Sallard, Erwan ^a   Lescure, François Xavier ^b,c   Yazdanpanah, Yazdan ^b,c   Mentre, France ^b   Peiffer Smadja, Nathan ^b,c  

^a ECOLE NORMALE SUPÉRIEURE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

COVID 19; Interferon; SARS CoV 2

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; BETA1A INTERFERON; INTERFERON; INTERFERON BETA SERINE; ANTIVIRUS AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CORONAVIRUS DISEASE 2019; DRUG MECHANISM; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS REPLICATION; BETACORONAVIRUS; CORONAVIRUS INFECTION; ISOLATION AND PURIFICATION; PANDEMIC; VIROLOGY; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; INTERFERON TYPE I; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85082856980     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2020.104791     Document Type: Article

References (42)

1. Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 20 (2014), 42–46, 10.1016/j.ijid.2013.12.003.
2. Arabi, Y.M., Shalhoub, S., Al-Omari, A., Mandourah, Y., Al-Hameed, F., Sindi, A., Alraddadi, B., Al-Motairi, A., Al-Khatib, K., Abdul-Mommin, A., Qushmaq, I.A., Mady, A., Solaiman, O., Al-Aithan, A., Balkhy, H.H., Al-Raddadi, R., Rajab, A., Al-Mekhlafi, G.A., Al-Harthy, A., Kharaba, A., Al-Jabbary, A., Pinto, R., Sadat, M., Al-Mutairi, H., Al-Qasim, E., Jose, J., Deeb, A.M., Merson, L., Hayden, F.G., Fowler, R., Aldawood, A.S., Effect of ribavirin and interferon on the outcome of critically ill patients with MERS. Am. J. Respir. Crit. Care Med., 195, 2017, A6067.
3. Arabi, Y.M., Alothman, A., Balkhy, H.H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A.M., Assiri, A.M., Al-Hameed, F., AlSaedi, A., Mandourah, Y., Almekhlafi, G.A., Sherbeeni, N.M., Elzein, F.E., Memon, J., Taha, Y., Almotairi, A., Maghrabi, K.A., Qushmaq, I., Al Bshabshe, A., Kharaba, A., Shalhoub, S., Jose, J., Fowler, R.A., Hayden, F.G., Hussein, M.A., Martin, G.S., Schoenfeld, D.A., Walmsley, S.L., Carson, S., Harbi, S. Al, Jeraisy, M. Al, Muhaidib, M. Al, Musharaf, S., Anizi, H. Al, Dael, R., AlMazroa, M., Asiri, A., Memish, Z.A., Ghazal, S.S., Alfaraj, S.H., Harthy, A. Al, Sulaiman, M. Al, Mady, A., Ahmad, A., Almekhlafi, Ghaleb A., Muhammed, R., Samirrai, S. Al, Awad, S., Cabal, R.C., Onazi, B. Al, Aljuhani, M., Vince, M., Enani, M. Al, Alqurashi, A., Alenezi, F., Alkhani, N., Thaqafi, A., Oraabi, O. Al, Rifai, J., Elsamadisi, P., Medhat, S.H., Basher, S.A.B., Abduldhaher, M., Bajhamoum, W., Alahsa, S.S., Bashir, S., Al-Dossary, I., Al-Muhainy Dammam, B., Khobar, S.S. Al, Alshahrani, M.S., Al Jabri, A., Farid, M., Alaidarous, A., Alseraihi, W., Shahada, H., Taif, J.S., Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19 (2018), 1–13, 10.1186/s13063-017-2427-0.
4. Bellingan, G., Maksimow, M., Howell, D.C., Stotz, M., Beale, R., Beatty, M., Walsh, T., Binning, A., Davidson, A., Kuper, M., Shah, S., Cooper, J., Waris, M., Yegutkin, G.G., Jalkanen, J., Salmi, M., Piippo, I., Jalkanen, M., Montgomery, H., Jalkanen, S., The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir. Med. 2 (2014), 98–107, 10.1016/S2213-2600(13)70259-5.
5. Belhadi, D., Peiffer-Smadja, N., Yazdanpanah, Y., Mentré, F., Laouénan, C., A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv. January, 2020, 10.1101/2020.03.18.20038190 2020.03.18.20038190.
6. Chan, J.F.W., Chan, K.H., Kao, R.Y.T., To, K.K.W., Zheng, B.J., Li, C.P.Y., Li, P.T.W., Dai, J., Mok, F.K.Y., Chen, H., Hayden, F.G., Yuen, K.Y., Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67 (2013), 606–616, 10.1016/j.jinf.2013.09.029.
7. Chan, J.F.W., Yao, Y., Yeung, M.L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J.P., Chu, H., Zhou, J., Chen, H., Qin, C., Yuen, K.Y., Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212 (2015), 1904–1913, 10.1093/infdis/jiv392.
8. Channappanavar, R., Fehr, A.R., Zheng, J., Wohlford-Lenane, C., Abrahante, J.E., Mack, M., Sompallae, R., McCray, P.B., Meyerholz, D.K., Perlman, S., IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest. 129 (2019), 3625–3639, 10.1172/JCI126363.
9. Chen, F., Chan, K.H., Jiang, Y., Kao, R.Y.T., Lu, H.T., Fan, K.W., Cheng, V.C.C., Tsui, W.H.W., Hung, I.F.N., Lee, T.S.W., Guan, Y., Peiris, J.S.M., Yuen, K.Y., In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 31 (2004), 69–75, 10.1016/j.jcv.2004.03.003.
10. Dong, L., Hu, S., Gao, J., Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 14 (2020), 58–60, 10.5582/ddt.2020.01012.
11. Falzarano, D., De Wit, E., Martellaro, C., Callison, J., Munster, V.J., Feldmann, H., Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 3 (2013), 1–6, 10.1038/srep01686.
12. Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S.A., Palese, P., Baric, R.S., Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/golgi membrane. J. Virol. 81 (2007), 9812–9824, 10.1128/jvi.01012-07.
13. Gao, L.L., Yu, S., Chen, Q., Duan, Z., Zhou, J., Mao, C., Yu, D., Zhu, W., Nie, J., Hou, Y., A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine 28 (2010), 4445–4451, 10.1016/j.vaccine.2010.03.062.
14. Hart, B.J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R.F., Olinger, G.G., Frieman, M.B., Holbrook, M.R., Jahrling, P.B., Hensley, L., Interferon-β and mycophenolic acid are potent inhibitors of middle east respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 95 (2014), 571–577, 10.1099/vir.0.061911-0.
15. Hensley, L.E., Fritz, E.A., Jahrling, P.B., Karp, C.L., Huggins, J.W., Geisbert, T.W., Interferon-β 1a and SARS coronavirus replication. Emerg. Infect. Dis. 10 (2004), 317–319, 10.3201/eid1002.030482.
16. Jakimovski, D., Kolb, C., Ramanathan, M., Zivadinov, R., Weinstock-Guttman, B., Interferon β for multiple sclerosis. Cold Spring Harb. Perspect. Med. 8 (2018), 1–20, 10.1101/cshperspect.a032003.
17. Kopecky-Bromberg, S.A., Martinez-Sobrido, L., Frieman, M., Baric, R.A., Palese, P., Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 81 (2007), 548–557, 10.1128/jvi.01782-06.
18. Lai, C.C., Shih, T.P., Ko, W.C., Tang, H.J., Hsueh, P.R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents, 55, 2020, 105924, 10.1016/j.ijantimicag.2020.105924.
19. Liu, Y.-J., IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23 (2005), 275–306, 10.1146/annurev.immunol.23.021704.115633.
20. Lokugamage, K.G., Schindewolf, C., Menachery, V.D., SARS-CoV-2 sensitive to type I interferon pretreatment. BioRxiv, 2020, 10.1101/2020.03.07.982264.
21. Loutfy, M.R., Blatt, L.M., Siminovitch, K.A., Ward, S., Wolff, B., Lho, H., Pham, D.H., Deif, H., LaMere, E.A., Chang, M., Kain, K.C., Farcas, G.A., Ferguson, P., Latchford, M., Levy, G., Dennis, J.W., Lai, E.K.Y., Fish, E.N., Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. J. Am. Med. Assoc. 290 (2003), 3222–3228, 10.1001/jama.290.24.3222.
22. Lu, H., Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience Trends, 2020, 10.5582/bst.2020.01020.
23. Mager, D.E., Jusko, W.J., Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β1a in humans. Pharm. Res. (N. Y.) 19:10 (2002), 1537–1543, 10.1023/A:1020468902694.
24. Martinez, M.A., Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob. Agents Chemother., 1–18, 2020, 10.1128/AAC.00399-20.
25. Menachery, V.D., Yount, B.L., Josset, L., Gralinski, L.E., Scobey, T., Agnihothram, S., Katze, M.G., Baric, R.S., Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2’-O-methyltransferase activity. J. Virol. 88 (2014), 4251–4264, 10.1128/jvi.03571-13.
26. Morgenstern, B., Michaelis, M., Baer, P.C., Doerr, H.W., Cinatl, J., Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun. 326 (2005), 905–908, 10.1016/j.bbrc.2004.11.128.
27. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., Almakhlafi, G.A., Albarrak, M.M., Memish, Z.A., Albarrak, A.M., Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 14 (2014), 1090–1095, 10.1016/S1473-3099(14)70920-X.
28. Ranieri, V.M., Pettilä, V., Karvonen, M.K., Jalkanen, J., Nightingale, P., Brealey, D., Mancebo, J., Ferrer, R., Mercat, A., Patroniti, N., Quintel, M., Vincent, J.L., Okkonen, M., Meziani, F., Bellani, G., MacCallum, N., Creteur, J., Kluge, S., Artigas-Raventos, A., Maksimow, M., Piippo, I., Elima, K., Jalkanen, S., Jalkanen, M., Bellingan, G., Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. JAMA, J. Am. Med. Assoc. 323 (2020), 725–733, 10.1001/jama.2019.22525.
29. Sainz, B., Mossel, E.C., Peters, C.J., Garry, R.F., Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329 (2004), 11–17, 10.1016/j.virol.2004.08.011.
30. Samuel, C.E., Antiviral actions of interferons. Clin. Microbiol. Rev. 14 (2001), 778–809, 10.1128/CMR.14.4.778-809.2001.
31. Scagnolari, C., Vicenzi, E., Bellomi, F., Stillitano, M.G., Pinna, D., Poli, G., Clementi, M., Dianzani, F., Antonelli, G., Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir. Ther. 9 (2004), 1003–1011.
32. Schneider, W.M., Chevillotte, M.D., Rice, C.M., Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32 (2014), 513–545, 10.1146/annurev-immunol-032713-120231.
33. Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., Mushtaq, A., IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J. Antimicrob. Chemother. 70 (2015), 2129–2132, 10.1093/jac/dkv085.
34. Sheahan, T.P., Sims, A.C., Leist, S.R., Schäfer, A., Won, J., Brown, A.J., Montgomery, S.A., Hogg, A., Babusis, D., Clarke, M.O., Spahn, J.E., Bauer, L., Sellers, S., Porter, D., Feng, J.Y., Cihlar, T., Jordan, R., Denison, M.R., Baric, R.S., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun., 11, 2020, 10.1038/s41467-019-13940-6.
35. Shen, K.L., Yang, Y.H., Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J. Pediatr., 2020, 6–8, 10.1007/s12519-020-00344-6.
36. Siddiqi, H.K., Mehra, M.R., COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart Lung Transplant., 2020.
37. Stockman, L.J., Bellamy, R., Garner, P., SARS: systematic review of treatment effects. PLoS Med. 3 (2006), 1525–1531, 10.1371/journal.pmed.0030343.
38. Thiel, V., Weber, F., Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev. 19 (2008), 121–132, 10.1016/j.cytogfr.2008.01.001.
39. Totura, A.L., Baric, R.S., SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr. Opin. Virol. 2 (2012), 264–275, 10.1016/j.coviro.2012.04.004.
40. Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., Zeng, X., Zhang, S., The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin. Immunol., 214, 2020, 108393, 10.1016/j.clim.2020.108393.
41. Zhao, Z., Zhang, F., Xu, M., Huang, K., Zhong, W., Cai, W., Yin, Z., Huang, S., Deng, Z., Wei, M., Xiong, J., Hawkey, P.M., Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J. Med. Microbiol. 52 (2003), 715–720, 10.1099/jmm.0.05320-0.
42. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:10229 (2020), 1054–1062, 10.1016/S0140-6736(20)30566-3.